JNJ vs KROS

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Keros Therapeutics still possesses significant long-term 10x potential due to its deep pipeline targeting large unmet medical needs via the validated TGF-beta pathway. The Takeda licensing deal for KER-012, now progressing to Phase 3, validates the platform and offers future milestones. However, recent Q1 2026 earnings were abysmal, showing a near 100% year-over-year revenue decline and a swing to...